Literature DB >> 26853255

Higher cancer antigen 125 level is associated with the presence of permanent atrial fibrillation in systolic heart failure patients.

Hakki Kaya, Ali Zorlu, Hasan Yucel, Mustafa Adem Tatlisu, Tarik Kivrak, Abuzer Coskun, Mehmet Birhan Yilmaz.   

Abstract

INTRODUCTION: Atrial fibrillation (AF) is a common arrhythmia in heart failure (HF). Recent studies have shown that serum cancer antigen-125 (CA-125) levels are elevated in HF, and high levels of CA-125 in HF patients with sinus rhythm have been shown to be associated with the development of new onset AF. However, the relation between CA-125 levels and the presence of AF in HF is unknown. In this study we investigated whether plasma CA-125 levels in patients with systolic HF could predict the presence of AF.
METHODS: The study was a retrospective cohort design including 205 stable systolic HF patients who were selected during outpatient clinic visits and who had CA-125 measurement and an electrocardiogram within the last one month before admittance to cardiology clinic. Patients were classified into two groups based on the presence of AF (n = 67) or sinus rhythm (n = 138).
RESULTS: The mean age of the patients was 68 ± 11 years. CA-125 levels were significantly higher in patients with AF than patients with SR [33 (3-273) vs 102 (7-296) U/ml, P < 0.001]. CA-125 level, presence of right ventricular dilatation, pericardial effusion, moderate to severe TR and MR, and left atrial diameter were found to be associated with the presence of AF in univariate analysis. In a multivariate logistic regression model, only the CA-125 level remained associated. Also, according to the ROC curve analysis, the optimal cut-off level of CA-125 for predicting AF was ≥ 91 U/mL with a specificity of 84% and a sensitivity of 54%.
CONCLUSION: We have shown that the CA-125 levels can be used to predict AF in patients with systolic HF.

Entities:  

Keywords:  Cancer antigen-125 | CA-125 | systolic heart failure | atrial fibrillation

Mesh:

Substances:

Year:  2016        PMID: 26853255     DOI: 10.2143/AC.71.1.3132099

Source DB:  PubMed          Journal:  Acta Cardiol        ISSN: 0001-5385            Impact factor:   1.718


  6 in total

Review 1.  Redefining biomarkers in heart failure.

Authors:  Michele Correale; Ilenia Monaco; Natale Daniele Brunetti; Matteo Di Biase; Marco Metra; Savina Nodari; Javed Butler; Mihi Gheorghiade
Journal:  Heart Fail Rev       Date:  2018-03       Impact factor: 4.214

2.  Plasma carbohydrate antigen-125 for prediction of atrial fibrillation recurrence after radiofrequency catheter ablation.

Authors:  Qingya Wang; Chengjing Dang; Haoyu Liu; Jie Hui
Journal:  BMC Cardiovasc Disord       Date:  2021-08-19       Impact factor: 2.298

3.  Relationship Between Carbohydrate Antigen 125 and Coronary Artery Calcification in Patients without Known Coronary Artery Disease.

Authors:  Kun Fu; Hua-Dong Liu; KuerBanJiang MaMuTi; Dong-Nan Hu; Peng Hao
Journal:  Med Sci Monit       Date:  2018-05-07

4.  Cancer antigen-125 and risk of atrial fibrillation: a systematic review and meta-analysis.

Authors:  Angel Cheung; Mengqi Gong; Roberto Bellanti; Sadeq Ali-Hasan-Al-Saegh; Guangping Li; Eulàlia Roig; Julio Núñez; Thomas D Stamos; Mehmet Birhan Yilmaz; Kaya Hakki; William K K Wu; Sunny Hei Wong; Wing Tak Wong; George Bazoukis; Konstantinos Lampropoulos; Lah Ah Tse; Jichao Zhao; Gregory Y H Lip; Adrian Baranchuk; Martin C S Wong; Tong Liu; Gary Tse
Journal:  Heart Asia       Date:  2018-01-07

5.  Cancer antigen-125 plasma level as a biomarker of new-onset atrial fibrillation in postmenopausal women.

Authors:  Haruki Sekiguchi; Ken Shimamoto; Mayu Takano; Makiko Kimura; Yufuko Takahashi; Fujio Tatsumi; Eri Watanabe; Kentaro Jujo; Naoko Ishizuka; Masatoshi Kawana; Nobuhisa Hagiwara
Journal:  Heart       Date:  2017-03-11       Impact factor: 5.994

6.  CA125 as a Marker of Heart Failure in the Older Women: Population-Based Analysis.

Authors:  Weronika Bulska-Będkowska; Elżbieta Chełmecka; Aleksander J Owczarek; Katarzyna Mizia-Stec; Andrzej Witek; Aleksandra Szybalska; Tomasz Grodzicki; Magdalena Olszanecka-Glinianowicz; Jerzy Chudek
Journal:  J Clin Med       Date:  2019-05-03       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.